Opioids, NSAIDs no different overall for persistent pain after vehicle crashes

November 21, 2016 by David Orenstein  
Overall, emergency patients given NSAID painkillers were no more likely to report persistent pain six weeks after a car crash than comparable patients given opioids. But the opioids were more likely to still be in use, raising concerns about dependence. Credit: Pixabay

Persistent pain is common among the nearly 4 million Americans who arrive each year at hospital emergency departments (EDs) after car crashes. A new study in the journal Pain that compared the two most common pain-relief drugs—NSAIDs such as ibuprofen and opioids such as oxycodone—found that the risk of reporting persistent pain six weeks after a crash was not statistically different among patients prescribed either medication at the ED.

What did differ significantly was the likelihood that people initially prescribed , which can be addictive, would still be using them by that time.

"You'd think there would be a wealth of studies comparing our 'go-to' , but there just aren't," said Dr. Francesca Beaudoin, lead author of the study, assistant professor of emergency medicine in Brown University's Warren Alpert School of Medicine and an ED physician at Rhode Island Hospital.

"But now that opioids are under fire, it's forcing us to ask: What is the best treatment, who is it best for and under what conditions? As an emergency physician, I prescribe these drugs all the time. Does what I am giving to people have any impact on the pain outcomes that matter to them?"

Comparing cases

To produce an informative comparison, Beaudoin teamed with researchers including Roee Gutman, assistant professor of biostatistics in the Brown University School of Public Health, to analyze the prescribing and pain outcomes at six weeks of 948 people who experienced . Their data was drawn from a larger study conducted in eight hospitals in Florida, Massachusetts, Michigan and New York between February 2009 and October 2011.

In the analysis, the researchers were careful to make fair comparisons between the two analgesics by comparing cases that were as similar as possible, except in which of the two was prescribed. In all, they considered more than 50 variables—from socio-demographic characteristics of the to baseline reported pain to which body regions hurt, the characteristics of the crash and patient medical history—in matching cases for comparison. This kind of statistical accounting was important because, for example, patients who were prescribed opioids were ones who reported greater pain levels in the ED. Without controlling for that, any comparison between opioids and NSAIDs would have been unfair to opioids because they were prescribed to patients who at baseline had more pain.

"We tried to find 'twins' where one got the opioid and the other got the NSAID," Gutman said.

In the final analysis, they were able to compare 284 of the cases head-to-head.

What the researchers found is that six weeks after their crash, similar patients were 7.2 percent more likely to report moderate to severe pain if they were prescribed opioids than NSAIDS; however, this difference was too small to be statistically significant.

In all of the cases, patients were prescribed a supply of pain medications to last just a few days, but the researchers measured a significantly larger risk, 17.5 percent, that people prescribed opioids were still using opioids after six weeks than people prescribed NSAIDs would be using NSAIDs.

Individualized treatment

Though there were no significant differences in pain risk overall, Beaudoin and Gutman said they saw signs that different patients responded differently to pain management. Some likely would benefit most from opioids, some from NSAIDs, some to neither, and some could have used either.

Based on the data, they wrote, they could predict: "Approximately one in five individuals would not have persistent moderate or severe pain six weeks after [a crash] if they were prescribed an opioid, but they would have had moderate to had they been prescribed an NSAID. Conversely, one in four patients would have only experienced such treatment success with an NSAID."

The next step in the research, Beaudoin said, is to try to identify what characteristics best predict which therapy is best for which patients. Such a system could help doctors manage patients' while only prescribing opioids for people who really need them.

"Wouldn't it be nice if I had a tool I could use to ask maybe five questions and know which treatment you would be most likely to benefit from?" Beaudoin asked.

Explore further: Many back pain patients get limited relief from opioids and worry about taking them

More information: Francesca L. Beaudoin et al, Persistent pain after motor vehicle collision, PAIN (2016). DOI: 10.1097/j.pain.0000000000000756

Related Stories

Many back pain patients get limited relief from opioids and worry about taking them

October 23, 2016
Millions of people take opioids for chronic back pain, but many of them get limited relief while experiencing side effects and worrying about the stigma associated with taking them, suggests research presented at the Anesthesiology ...

Patients who are not prescribed opioids find more improvements in physical function, study

January 22, 2016
Opioids such as morphine, codeine and Tylenol 3 can be effective for treating pain, however, a new University of Alberta study finds that patients with neuropathic pain taking opioids report no improvements in physical functioning ...

Opioids increase risk of death when compared to other pain treatments

June 14, 2016
Long-acting opioids are associated with a significantly increased risk of death when compared with alternative medications for moderate-to-severe chronic pain, according to a Vanderbilt study released today in JAMA.

Opioids may not spell relief for chronic back pain sufferers with depression, anxiety

July 9, 2015
Although opioids are frequently prescribed to treat chronic lower back pain, new research suggests these powerful medications may be less effective in some patients. A study published in the Online First edition of Anesthesiology, ...

Physical therapy is best choice for pain management

August 29, 2016
According to the Centers for Disease Control and Prevention (CDC), sales of prescription opioids have quadrupled in the United States since 1999, even though there has not been an overall change in the amount of pain reported.

New analysis recommends responsible prescription of opioids to pain patients

July 13, 2016
A recent review and analysis suggests that some policies restricting opioid prescriptions to curb overdose deaths could be harming those who need them the most: pain patients.

Recommended for you

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

Non-psychotropic cannabinoids show promise for pain relief

September 4, 2017
Some cancers love bone. They thrive in its nutrient-rich environment while gnawing away at the very substrate that sustains them, all the while releasing inflammatory substances that cause pain—pain so severe that opioids ...

Fentanyl drives rise in opioid-linked deaths in U.S.

August 31, 2017
(HealthDay)—Fentanyl, a synthetic narcotic, is a key player in America's continuing epidemic of opioid-related overdose deaths, two new studies report.

Eating triggers endorphin release in the brain

August 28, 2017
Finnish researchers have revealed how eating stimulates brain's endogenous opioid system to signal pleasure and satiety.

Cholesterol-lowering drugs may fight infectious disease

August 21, 2017
That statin you've been taking to lower your risk of heart attack or stroke may one day pull double duty, providing protection against a whole host of infectious diseases, including typhoid fever, chlamydia, and malaria.

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.